Report Package: Hot targets for empowered antibody and cell therapy technologies

This package contains three reports analyzing

  • BCMA,

  • CD123 and

  • CD22

as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:

  • Fc-Engineered Antibodies;

  • Radioimmunotherapy;

  • Immunotoxins;

  • Antibody-Drug Conjugates;

  • T-Cell Redirecting Bispecific Antibodies;

  • Chimeric Antigen Receptor (CAR) T-Cells.

The reports describe and discuss

  • Target background, scientific rationale & expression profiles;

  • Preclinical proof-of-concept;

  • Clinical experience;

  • Competitive landscape;

  • Drug or cell therapy profiles;

  • Company profiles.

Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

CD123: a paradigmatic target for immunotherapeutic treatment modalities

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.